Summary of Key Points Core Viewpoint - Western Securities (002673) is experiencing a slight decline in stock price, with a reported closing price of 7.41 yuan on May 30, 2025, down by 0.67% [1]. Trading Information - On May 30, 2025, the fund flow for Western Securities indicated a net outflow of 5.39 million yuan from major funds, while retail funds saw a net inflow of 5.57 million yuan [2][4]. - The trading volume was 188,900 shares, with a total transaction amount of 140 million yuan [1]. Company Announcements - Western Securities announced the payment of interest for its publicly issued corporate bonds (second phase) on June 4, 2025. The interest amount is 2.29 yuan (including tax) per bond for the period from June 4, 2024, to June 3, 2025 [2][4]. - The bond issuance scale is 1 billion yuan, with a maturity of three years and a coupon rate of 2.29%. The bonds are issued at par value, with interest payments scheduled annually on June 4 from 2025 to 2027, and the redemption date is June 4, 2027 [2]. - The bonds are unsecured and have a credit rating of AAA. Each bond (with a face value of 1,000 yuan) will distribute interest of 22.90 yuan (including tax) [2].

Group 1 - The company West Securities Co., Ltd. announced the issuance of its corporate bonds (second phase) aimed at professional investors, with a total issuance scale of 1 billion yuan and a maturity period of 3 years [1] - The coupon rate for the bonds is set at 2.29%, with interest payments amounting to 22.90 yuan per bond (before tax) for each 1,000 yuan face value [1] - The bond's credit rating is AAA and it is unsecured, with the next interest payment date scheduled for June 4, 2025, maintaining the same interest rate [1] Group 2 - The interest payment date is June 4, 2025, with the record date for bondholders being June 3, 2025, and payments will be made through China Securities Depository and Clearing Corporation [1] - Individual and securities investment fund holders will receive a net interest of 18.32 yuan per bond after tax, while non-resident enterprises will receive the full amount of 22.90 yuan [1] - The company has committed to timely interest payments and will announce any subsequent arrangements in case of special circumstances affecting the payment process [1]

| 证券代码：002673 证券简称：西部证券 | 公告编号：2025-039 | | --- | --- | | 债券代码：149949 | 债券简称：22西部06 | | 148177 | 23西部02 | | 148339 | 23西部03 | | 148391 | 23西部04 | | 148424 | 23西部05 | | 148699 | 24西部01 | | 148753 | 24西部02 | | 148865 | 24西部03 | | 148924 | 24西部04 | | 524008 | 24西部05 | | 524106 | 25西部01 | | 524164 | 25西部02 | 西部证券股份有限公司 2024年面向专业投资者公开发行公司债券 （第二期）2025年付息公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 一、本期债券基本情况 1、发行主体：西部证券股份有限公司 2、债券名称：西部证券股份有限公司2024年面向专业投资者公 开发行公司债券（第二期） 3、债券简称：24西部02 西部证券股份有限公司 2024 年 ...

西部证券股份有限公司 关于湖南艾布鲁环保科技股份有限公司 使用部分暂时闲置募集资金及闲置自有资金进行现金管理的核查意 （证监许可2022495 号） 核准，湖南艾布鲁环保科技股份有限公司（以下简称"公司"）首次公开发行人民 币普通股（A 股）30,000,000 股，每股面值人民币 1 元,每股发行价格为 18.39 元， 募集资金总额为 551,700,000.00 元，扣除承销保荐费（不含税）41,637,735.85 元 和 其 他 相 关 发 行 费 用 （ 不 含 税 ） 18,476,483.78 元 后 ， 实 际 募 集 资 金 净 额 会计师事务所（特殊普通合伙）已于 2022 年 4 月 21 日对公司首次公开发行股票 的资金到位情况进行了审验，并出具了"CAC 证验字20220035 号" 《验资报告》。 为规范公司募集资金管理，保护投资者权益，公司与保荐人、募集资金专户 开户银行签署了《募集资金三方监管协议》，开设了募集资金专项账户，对募集 资金实行专户存储。上述全部募集资金已按规定存放于公司募集资金专户。 二、募集资金投资项目情况 见 西部证券股份有限公司（以下简称"西部证券"或"保 ...

证券代码：【 524283 】 证券简称：【 25 西部 K1 】 西部证券股份有限公司 2025 年面向专业投资者公开发行科技创 特此公告。 （本页以下无正文） 本公司及其董事、监事、高级管理人员保证公告内容真实、准确和完整， 并对 公告中的虚假记载、误导性陈述或者重大遗漏承担责任。 西部证券股份有限公司（以下简称"发行人"）发行不超过人民币 180 亿元 公司债券已获得中国证券监督管理委员会证监许可﹝2024﹞60 号文注册。西部 证券股份有限公司 2025 年面向专业投资者公开发行科技创新公司债券（第一期） （以下 简称"本期债券"）发行规模为不超过（含）10 亿元。 2025 年 5 月 29 日，发行人和主承销商在网下向专业机构投资者进行了票面 利率询价，利率询价区间为 1.5%-2.5%。根据网下向专业机构投资者询价结果， 经发行人和主承销商协商一致，最终确定本次债券票面利率为【1.92】% 。 发行人将按上述票面利率于 2025 年 5 月 30 日面向专业机构投资者网下发 行。具体认购方法请参考 2025 年 5 月 27 日刊登在深圳证券交易所网站 （http://www.szse.cn）、 ...

(本页无正文,为《关于延长西部证券股份有限公司 2025 年面向专业投资者公 开发行科技创新公司债券(第一期)簿记建档时间的公告》之盖章页) 发行人:西部记 2025 (本页无正文,为《关于延长西部证券股份有限公司 2025年面向专业投资者公 开发行科技创新公司债券(第一期)簿记建档时间的公告》之盖章页） 关于延长西部证券股份有限公司 2025 年面向专业投资者公开发行科技创 新公司债券（第一期）簿记建档时间的公告 西部证券股份有限公司（以下简称"发行人"）面向专业投资者公开发行总额 不超过 180 亿元公司债券（以下简称"本次债券"）已获得中国证券监督管理委员 会《关于同意西部证券股份有限公司面向专业投资者公开发行公司债券注册的批 复》（证监许可﹝2024﹞60 号）。西部证券股份有限公司 2025 年面向专业投资 者公开发行科技创新公司债券（第一期）（以下简称"本期债券"）发行规模不 超过 10 亿元（含 10 亿元）。 根据《西部证券股份有限公司 2025 年面向专业投资者公开发行科技创新公 司债券（第一期）发行公告》，发行人和主承销商将于【2025】年【5】月【29】 日【15】：00 至【18】：0 ...

Core Viewpoint - Anke Biotech aims for restorative growth in 2025, focusing on enhancing sales of water injections and promoting the recovery of growth hormone sales while optimizing its traditional Chinese medicine segment and expanding its peptide and chemical drug markets [2][4][5]. Business Strategy - The company plans to strengthen academic promotion and increase the sales proportion of water injections, while also pushing for the recovery of growth hormone sales [2]. - The traditional Chinese medicine segment has resumed production since December 2024, with efforts to optimize sales policies and maintain growth in traditional Chinese medicine [2]. - The peptide segment will focus on market analysis and expanding the sales scale of raw materials for enterprises that win centralized procurement bids [2]. - The company intends to divest its forensic-related business and actively transition to new business areas [2]. Investment Activities - Anke Biotech has made cornerstone investments in Weisheng Pharmaceutical, aiming to establish a long-term cooperative relationship and enhance strategic collaboration to improve risk resistance and core competitiveness [3]. Sales Performance - In Q1 2025, the company reported a year-on-year increase in new patients for growth hormone, reversing a previous decline, with shipping showing an upward trend [4]. - The product Trastuzumab is in a rapid market introduction phase, with sales exceeding 100 million yuan in 2024 and expected significant year-on-year growth in 2025 [5]. Research and Development - The company is advancing several clinical trials, including Hu1 injection for HER2 targets, which has shown promising safety and efficacy in early studies [6]. - The recombinant anti-VEGF humanized monoclonal antibody has completed phase III clinical trials, and the company is working on its market application [6]. - The company is also developing innovative drugs targeting HER2 and has submitted IND applications for several projects [6]. Financial Overview - In Q1 2025, Anke Biotech reported a main revenue of 629 million yuan, a year-on-year decrease of 4.17%, and a net profit of 209 million yuan, also down 4.02% [8]. - The company has a debt ratio of 16.52% and a gross profit margin of 76.96% [8]. - Recent institutional ratings indicate a buy recommendation from two firms, with a target average price of 10.08 yuan [8].

Core Viewpoint - Major brokerages are optimistic about the A-share market in the second half of 2025, anticipating a structural bull market driven by multiple policy benefits and industrial upgrades [1][2]. Market Outlook - Brokerages such as Industrial Securities, CITIC Securities, and Everbright Securities predict a "structural bull" market for the capital market in the second half of 2025 [2]. - Industrial Securities' chief strategist Zhang Yidong believes that A-shares will exhibit characteristics of "stable index, structural bull" in the long term, highlighting the attractive valuation of Chinese assets [2]. - CITIC Securities' chief A-share strategist Qiu Xiang expects a bull market for equity assets starting from Q4 2025, with a significant shift in market style towards core assets [2]. - Everbright Securities' chief strategist Zhang Yusheng notes that the gradual recovery of fundamentals, along with macro and micro liquidity, will drive market growth, leading to a structural bull market [2][3]. Sector Preferences - Investment opportunities in the second half of the year should focus on four key areas according to Industrial Securities' chief strategist Zhang Qiyao: technology trends marked by DeepSeek, domestic service consumption, dividend assets, and sectors like gold and military [4]. - Qiu Xiang emphasizes the importance of increasing allocations to Hong Kong stocks and focusing on leading companies in emerging and traditional industries [4]. - Open Source Securities' chief strategist Wei Jixing suggests five focus areas: domestic consumption, technology growth in AI and robotics, industries with improved costs, sectors benefiting from overseas opportunities, and stable dividend stocks [4]. - Li Chao from Zheshang Securities advocates for a focus on dividend-related sectors and technology, anticipating adjustments in institutional allocation due to new public fund regulations [4].

Group 1 - The securities industry is entering a new development opportunity period, with firms planning to optimize business layouts and enhance investor returns through increased dividend frequency and cautious mergers and acquisitions [1][2] - Many listed securities firms have emphasized maintaining a stable dividend policy, with some planning to increase the proportion of cash dividends from at least 10% to at least 30% of distributable profits from 2024 to 2026 [2] - Companies are focusing on improving information disclosure quality and investor relations management to enhance long-term investment value and protect investor rights [2][3] Group 2 - The trend of mergers and acquisitions in the securities industry is accelerating, with several firms actively pursuing acquisitions, such as Western Securities' acquisition of Guorong Securities [3] - Companies are in various stages of regulatory review and integration planning for their merger activities, indicating a proactive approach to industry consolidation [3] - Despite a recovery in industry performance, challenges remain, including declining commission rates and reduced investment banking projects, which are pressuring smaller firms [4][5] Group 3 - Smaller securities firms are facing increased competition due to rising industry concentration and declining fee rates, prompting them to explore differentiated strategies [5] - Leading firms are enhancing their comprehensive service capabilities, with some adopting advanced technologies like AI to improve service efficiency and quality [5][6] - The industry is experiencing a transformation in its profit models and competitive landscape, with firms like Shenwan Hongyuan focusing on building a first-class investment bank and enhancing core professional capabilities [6]

中国经济网北京5月28日讯 艾布鲁(301259.SZ)日前发布2024年年度报告和2025年一季度报告。2024 年，艾布鲁实现营业收入1.85亿元，同比增长3.78%；归属于上市公司股东的净利润-3084.21万元，上年 同期为-2755.18万元；归属于上市公司股东的扣除非经常性损益的净利润-5197.53万元，上年同期 为-3162.95万元；经营活动产生的现金流量净额1.34亿元，同比增长4.14%。 艾布鲁于2022年4月26日在深交所创业板上市，公开发行新股数量为3000万股，发行后总股本1.2亿 股，发行价格为18.39元/股，募集资金总额为5.52亿元，募集资金净额为4.92亿元。 艾布鲁实际募资净额比原拟募资多1.43亿元。公司2022年4月20日披露的招股书显示，艾布鲁原拟 募资3.49亿元，拟分别用于"土壤修复药剂与污水处理一体化设备生产基地建设项目""研发设计中心升 级建设项目""营销服务与技术支持网络建设项目""补充营运资金项目"。 艾布鲁保荐机构(主承销商)是西部证券，保荐代表人是薛冰、何勇。艾布鲁发行费用总额为6011.42 万元，其中西部证券获得保荐承销费4163.77万元。 ...